secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axonics, Inc. (—)
CIK:        0001603756
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001603756-24-000061
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axonics Q1 revenue $91.4M, up 29% YoY; gross margin record 75.8%
----------------------------------------------------------------

- Net loss $19.1M vs $9.2M prior year, includes $3.8M acquisition costs for Boston Scientific merger.
- Sacral neuromodulation revenue $71.7M (+30%), Bulkamid revenue $19.7M (+27%).
- Adjusted EBITDA $3.0M vs $0.9M prior year; $6M cash compensation added back due to halted equity grants.
- Cash and investments $349M as of March 31, 2024; no guidance issued.
- Pending merger with Boston Scientific; equity grants stopped Jan 2024, shifting $6M to cash compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/0001603756-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/axnx-20240430.htm
  HTML page:      https://secwatch.observer/filing/0001603756-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer